Verici Dx PLC Patient enrolment completed (1038K)
31 Agosto 2021 - 1:00AM
UK Regulatory
TIDMVRCI
RNS Number : 1038K
Verici Dx PLC
31 August 2021
Verici Dx plc
("Verici Dx" or the "Company")
Patient enrolment completed for clinical validation trial for
lead products Clarava (TM) and Tuteva (TM)
Verici Dx remains on track for completion of study end points by
the end of 2021 for lead products
Verici Dx plc (AIM: VRCI), a developer of advanced clinical
diagnostics for organ transplant, announces that patient enrolment
for a multi-centre observational clinical validation study for the
Company's lead products has concluded ahead of management
expectations. Early completion of enrolment supports that the
Company remains on track to complete the validation study for these
products by the end of 2021, in line with expectations set out in
the Company's admission document.
Verici Dx has partnered with eleven leading US and EU centres to
date to run a global, non-randomised study for the clinical
validation of Verici Dx's lead products, Clarava (TM) and Tuteva
(TM) .
The study uses next generation sequencing in the Verici Dx
laboratory to create transcriptomic profiles to validate
performance characteristics of the lead Verici Dx signature
tests.
Over the longer term, the study will also provide validation for
the Company's fibrosis test, called Protega(TM). Patient enrolment
continues for validation of Protega and is expected to complete by
Q3 2022. The end points of the validation study for this product
are expected to be reached up to two years after the completion of
enrolment, with data expected shortly thereafter around year-end
2024.
Sara Barrington, CEO of Verici Dx, said: "I am delighted to have
reached this key milestone ahead of our original expectations.
Since IPO our primary focus has been on the successful prosecution
of these clinical trials, as the first key step in commercialising
our innovative transplant products.
"We remain on track to have our two lead products fully tested
by the end of the year and look forward to reporting the data in Q1
2022."
Enquiries:
Verici Dx www.v ericidx .com
Sara Barrington, CEO Via Walbrook PR
Julian Baines, Chairman
Singer Capital Markets (Nominated Adviser Tel: 020 7496 3000
& Broker)
Aubrey Powell / Kailey Alyar / Tom
Salvesen
Walbrook PR Limited Tel: 020 7933 8780 or vericidx@walbrookpr.com
Paul McManus / Sam Allen Mob: 07980 541 893 / 07502 558 258
About Verici Dx plc www.vericidx.com
Verici Dx is developing and commercialising tests to understand
how a patient will and is responding to organ transplant, with an
initial focus on kidney transplants. The body's own immune system
poses a threat to a successful transplant or graft. Patients'
immune systems differ in how they respond to the presence of the
transplanted organ, characterising this response is called immune
phenotyping. Our products and solutions are underpinned by
extensive scientific research into the recipient's immune phenotype
and how that impacts on acute rejection, chronic injury and
ultimately failure of the transplant. These immuno-profile
signatures also inform clinicians as to the optimal strategy for
immunosuppressive and other therapies for the most successful
treatment to ensure graft acceptance with the least amount of side
effects.
The foundational research was driven by a deep understanding of
cell-mediated immunity and is enabled by access to expertly curated
collaborative studies in highly informative cohorts in kidney
transplant.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCPMMFTMTBJBTB
(END) Dow Jones Newswires
August 31, 2021 02:00 ET (06:00 GMT)
Verici Dx (LSE:VRCI)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Verici Dx (LSE:VRCI)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024
